Medicus Pharma Ltd. has entered into a new engagement with Deloitte LLP, appointing the firm as the exclusive lead financial adviser. The collaboration aims to identify one or more partners for an out-licensing transaction involving Doxorubicin Microneedle Array (D-MNA), a treatment for Basal Cell Carcinoma in adults. This agreement allows for flexibility in the transaction structure, which may include licensing or other mechanisms. Medicus Pharma Ltd. will compensate Deloitte with a retainer and a contingent success fee upon the successful completion of a transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.